Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Gilead Sciences, Inc. today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy ® plus Keytruda ® significantly improved progression-free ...

Gilead and Merck collaborated in 2021 to evaluate Trodelvy in combination with Keytruda in the phase III ASCENT-04/KEYNOTE-D19 study. Shares of GILD have gained 20% year to date against the ...

– First Pivotal Phase 3 Trial to Show Superiority of a TROP-2 Antibody-Drug Conjugate, Trodelvy, Plus Keytruda Versus Standard of Care in 1L Metastatic TNBC – – Early Trend in Improvement in ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with no new safety concerns.

Gilead and Merck combo's breast cancer win — The popular drug Trodelvy from Gilead in combination with Merck's blockbuster immunotherapy Keytruda l owered the risk of an aggressive type of ...

Gilead Sciences said Monday that a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women with a less common, but aggressive form of breast cancer.

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic ...